Targeting GID8: A Promising Approach To Drug Development (G54994)

Target Name: GID8

NCBI ID: G54994

GID8

Targeting GID8: A Promising Approach To Drug Development

GID8 (protein C20orf11) is a protein that is expressed in a wide range of tissues and cells in the human body. It is a key regulator of the cell division process, and is involved in the development and maintenance of tissues such as blood vessels, muscles, and bones. GID8 is also involved in the regulation of cell signaling pathways, and has been implicated in the development of a number of diseases, including cancer.

In recent years, researchers have been interested in finding new treatments for a variety of diseases, and GID8 has emerged as a promising target for drug development. GID8 has been shown to be involved in a number of different signaling pathways, including the TGF-β pathway, which is involved in the regulation of cell growth and differentiation.

One potential approach to targeting GID8 is to use small molecules, such as drugs that can modulate the activity of GID8. Researchers have been shown that GID8 is sensitive to a variety of small molecules, including inhibitors of the TGF-β pathway. These inhibitors have been shown to be effective in animal models of cancer, and could be used to treat cancer in humans.

Another potential approach to targeting GID8 is to use antibodies that can specifically recognize and target GID8. These antibodies have been shown to be effective in preclinical studies for treating a variety of diseases, including cancer.

In addition to its potential as a drug target, GID8 is also a potential biomarker for a variety of diseases. Its expression has been shown to be associated with the development of a number of diseases, including cancer, and its levels have been used as a biomarker for tracking the effectiveness of certain treatments.

Overall, GID8 is a protein that has the potential to be a drug target or biomarker for a variety of diseases. Further research is needed to fully understand its role and potential as a therapeutic agent.

Protein Name: GID Complex Subunit 8 Homolog

Functions: Core component of the CTLH E3 ubiquitin-protein ligase complex that selectively accepts ubiquitin from UBE2H and mediates ubiquitination and subsequent proteasomal degradation of the transcription factor HBP1 (PubMed:29911972). Acts as a positive regulator of Wnt signaling pathway by promoting beta-catenin (CTNNB1) nuclear accumulation (PubMed:28829046)

The "GID8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GID8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets